Can Broader Diffusion of Value-Based Insurance Design Increase Benefits from US Health Care without Increasing Costs? Evidence from a Computer Simulation Model
Background:
Evidence suggests that cost sharing (i.e.,copayments and deductibles) decreases health expenditures but also reduces essential care. Value-based insurance design (VBID) has been proposed to encourage essential care while controlling health expenditures. Our objective was to estimate the impact of broader diffusion of VBID on US health care benefits and costs.
Methods and Findings:
We used a published computer simulation of costs and life expectancy gains from US health care to estimate the impact of broader diffusion of VBID. Two scenarios were analyzed: (1) applying VBID solely to pharmacy benefits and (2) applying VBID to both pharmacy benefits and other health care services (e.g., devices). We assumed that cost sharing would be eliminated for high-value services (<$100,000 per life-year), would remain unchanged for intermediate- or unknown-value services ($100,000–$300,000 per life-year or unknown), and would be increased for low-value services (>$300,000 per life-year). All costs are provided in 2003 US dollars. Our simulation estimated that approximately 60% of health expenditures in the US are spent on low-value services, 20% are spent on intermediate-value services, and 20% are spent on high-value services. Correspondingly, the vast majority (80%) of health expenditures would have cost sharing that is impacted by VBID. With prevailing patterns of cost sharing, health care conferred 4.70 life-years at a per-capita annual expenditure of US$5,688. Broader diffusion of VBID to pharmaceuticals increased the benefit conferred by health care by 0.03 to 0.05 additional life-years, without increasing costs and without increasing out-of-pocket payments. Broader diffusion of VBID to other health care services could increase the benefit conferred by health care by 0.24 to 0.44 additional life-years, also without increasing costs and without increasing overall out-of-pocket payments. Among those without health insurance, using cost saving from VBID to subsidize insurance coverage would increase the benefit conferred by health care by 1.21 life-years, a 31% increase.
Conclusion:
Broader diffusion of VBID may amplify benefits from US health care without increasing health expenditures.
: Please see later in the article for the Editors' Summary
Vyšlo v časopise:
Can Broader Diffusion of Value-Based Insurance Design Increase Benefits from US Health Care without Increasing Costs? Evidence from a Computer Simulation Model. PLoS Med 7(2): e32767. doi:10.1371/journal.pmed.1000234
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1000234
Souhrn
Background:
Evidence suggests that cost sharing (i.e.,copayments and deductibles) decreases health expenditures but also reduces essential care. Value-based insurance design (VBID) has been proposed to encourage essential care while controlling health expenditures. Our objective was to estimate the impact of broader diffusion of VBID on US health care benefits and costs.
Methods and Findings:
We used a published computer simulation of costs and life expectancy gains from US health care to estimate the impact of broader diffusion of VBID. Two scenarios were analyzed: (1) applying VBID solely to pharmacy benefits and (2) applying VBID to both pharmacy benefits and other health care services (e.g., devices). We assumed that cost sharing would be eliminated for high-value services (<$100,000 per life-year), would remain unchanged for intermediate- or unknown-value services ($100,000–$300,000 per life-year or unknown), and would be increased for low-value services (>$300,000 per life-year). All costs are provided in 2003 US dollars. Our simulation estimated that approximately 60% of health expenditures in the US are spent on low-value services, 20% are spent on intermediate-value services, and 20% are spent on high-value services. Correspondingly, the vast majority (80%) of health expenditures would have cost sharing that is impacted by VBID. With prevailing patterns of cost sharing, health care conferred 4.70 life-years at a per-capita annual expenditure of US$5,688. Broader diffusion of VBID to pharmaceuticals increased the benefit conferred by health care by 0.03 to 0.05 additional life-years, without increasing costs and without increasing out-of-pocket payments. Broader diffusion of VBID to other health care services could increase the benefit conferred by health care by 0.24 to 0.44 additional life-years, also without increasing costs and without increasing overall out-of-pocket payments. Among those without health insurance, using cost saving from VBID to subsidize insurance coverage would increase the benefit conferred by health care by 1.21 life-years, a 31% increase.
Conclusion:
Broader diffusion of VBID may amplify benefits from US health care without increasing health expenditures.
: Please see later in the article for the Editors' Summary
Zdroje
1. NewhouseJP
1993 An iconoclastic view of health cost containment. Health Affairs (Millwood) 12 Suppl 152 171
2. GoldmanDP
JoyceGF
ZhengY
2007 Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA 298 61 69
3. Kaiser Family Foundation and Health Research and Educational Trust. Employer Health Benefits, 2007 summary of findings. Menlo Park (California): Henry J. Kaiser Family Foundation
4. TrivediAN
RakowskiW
AyanianJZ
2008 Effect of cost sharing on screening mammography in medicare health plans. N Engl J Med 358 375 383
5. ChernewME
ShahMR
WeghA
RosenbergSN
JusterIA
2008 Impact of decreasing copayments on medication adherence within a disease management environment. Health Affairs (Millwood) 27 103 112
6. RosenAB
HamelMB
WeinsteinMC
CutlerDM
FendrickAM
2005 Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 143 89 99
7. FendrickAM
SmithDG
ChernewME
ShahSN
2001 A benefit-based copay for prescription drugs: Patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care 7 861 867
8. ChernewME
RosenAB
FendrickAM
2007 Value-based insurance design. Health Aff (Millwood) 26 w195 203
9. BraithwaiteRS
RosenAB
2007 Linking cost sharing to value: An unrivaled yet unrealized public health opportunity. Ann Intern Med 146 602 605
10. NeumannPJ
RosenAB
WeinsteinMC
2005 Medicare and cost-effectiveness analysis. N Engl J Med 353 1516 1522
11. LambrewJM
2008 Testimony for the hearing “Getting Better Value in Health Care.” Testimony before the Committee on the Budget, US House of Representatives 16 July 2008. Available: http://budget.house.gov/hearings/2008/07.16lambrew.pdf. Accessed 08 September 2009
12. MahoneyJJ
2005 Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care 11 5 Suppl S170 176
13. BraithwaiteRS
MeltzerDO
KingJTJr
LeslieD
RobertsMS
2008 What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46 349 356
14. DevlinN
ParkinD
2004 Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13 437 452
15. UbelPA
HirthRA
ChernewME
FendrickAM
2003 What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163 1637 1641
16. MearaE
WhiteC
CutlerDM
2004 Trends in medical spending by age, 1963–2000. Health Aff (Millwood) 23 176 183
17. ProsserLA
StinnettAA
GoldmanPA
WilliamsLW
HuninkMG
2000 Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 132 769 779
18. PignoneM
EarnshawS
TiceJA
PletcherMJ
2006 Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis. Ann Intern Med 144 326 336
19. GoldmanDP
JoyceGF
Karaca-MandicP
2006 Varying pharmacy benefits with clinical status: The case of cholesterol-lowering therapy. Am J Manag Care 12 21 28
20. BraithwaiteRS
RobertsMS
JusticeAC
2007 Incorporating quality of evidence into decision analytic modeling. Ann Intern Med 146 133 141
21. FisherES
WennbergDE
StukelTA
GottliebDJ
LucasFL
2003 The implications of regional variations in medicare spending. part 2: Health outcomes and satisfaction with care. Ann Intern Med 138 288 298
22. GoldMR
SiegelJE
RussellLB
WeinsteinMC
1996 Cost-Effectiveness in Health and Medicine New York (New York) Oxford University Press
23. NewhouseJP
1993 Free for All? Lessons from the RAND Health Experiment Cambridge (Massachusetts) Harvard University Press
24. CherkinDC
GrothausL
WagnerEH
1989 The effect of office visit copayments on utilization in a health maintenance organization. Med Care 27(11) 1036 1045
25. SelbyJV
FiremanBH
SwainBE
1996 Effect of a copayment on use of the emergency department in a health maintenance organization. N Engl J Med 334 635 641
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2010 Číslo 2
- Jak rozpoznat pacienty s familiární hypercholesterolémií ve své praxi
- Myasthenia gravis: kombinace chirurgie a farmakoterapie jako nejefektivnější modalita?
- Statinová intolerance
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
Najčítanejšie v tomto čísle
- Packages of Care for Attention-Deficit Hyperactivity Disorder in Low- and Middle-Income Countries
- Measuring hsCRP—An Important Part of a Comprehensive Risk Profile or a Clinically Redundant Practice?
- Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis
- Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine: A Multi-country, Prospective Cohort Study